For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201014:nGNX2GBX5X


BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq:
APRE), a biopharmaceutical company focused on developing and commercializing
novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53,
today announced the launch of p53reactivation.com
(https://www.globenewswire.com/Tracker?data=PwBaeIoNC86HyhJ_RYeha8nm4aJWRI5UpjwNxpDqC81foHYRwQa4K2P3InEVecHgu4v_43-mz7-WfOSoSJ94lNTwykP-NN9dKTKw5ptGKME=).
The new website contributes to Aprea’s disease awareness initiative to
educate healthcare professionals on the importance of p53 mutations in cancer
and reactivation of mutant p53 as a potential therapeutic option for the
treatment of cancer.

“Mutations in p53 are present in approximately half of all cancers and are
often associated with poor treatment outcomes and resistance to traditional
anti-cancer therapies,” said Eyal Attar, M.D., Senior Vice President and
Chief Medical Officer of Aprea Therapeutics. “Knowledge of the poor
prognoses that accompany p53 mutations, the availability of diagnostic tests
for their identification, and awareness of mutant p53 reactivation as a
potential targeted therapeutic option, may collectively advance detection and
treatment for cancer patients with this important and significant unmet
medical need.”

Corporate Contacts:

Scott M. Coiante
Sr. Vice President and Chief Financial Officer
617-463-9385

Gregory A. Korbel
Vice President of Business Development
617-463-9385

Source: Aprea Therapeutics, Inc.


(https://www.globenewswire.com/NewsRoom/AttachmentNg/4b5be207-2832-49b4-9e6a-15869e433e16)



GlobeNewswire, Inc. 2020